Amid the tragic consequences of COVID-19, life sciences and medtech companies emerged as lights in the darkness. Decades of scientific work and investment seemed to be overnight successes. The heroic dedication of health care providers was met by the fastest novel vaccine development in history. Traditional competitors partnered to accelerate research and manufacturing. When one company failed, it joined the other to accelerate the development and manufacture of a successful vaccine. Governments, retail pharmacies, health systems, payers, and nonprofits are working together to provide widespread distribution and administration.

Overview and outlook 

Redesigning work, workplace, and workforce, while meeting individual needs

Accelerated digitization: New points of care, new roles for pharma and medtech

New customer-centric commercial model: Meeting physicians where they are,on their terms, and through more meaningful interactions

New types of collaborations and clinical trials reshaping research and development

Shortening development and review timelines, thinking more like a regulator